The present invention relates to benzothiophene, benzyloxybenzylidene and indoline-2-one derivatives and the use of said derivatives in the treatment and/or prevention of tuberculosis.

The present invention relates to benzothiophene, benzyloxybenzylidene and indoline-2-one derivatives and the use of said derivatives in the treatment and/or prevention of tuberculosis.

Disclosed herein are new antiviral compounds, together with pharmaceutical compositions that include one or more antiviral compounds, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a paramyxovirus viral infection with one or more small molecule compounds. Examples of paramyxovirus infection include an infection caused by human respiratory syncytial virus (RSV).

Disclosed herein are new antiviral compounds, together with pharmaceutical compositions that include one or more antiviral compounds, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a paramyxovirus viral infection with one or more small molecule compounds. Examples of paramyxovirus infection include an infection caused by human respiratory syncytial virus (RSV).

Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating diseases or disorders in a subject where the subject is in need of an inhibitor of MEK where the compound is according to formula (I): where R.sup.1, R.sup.2, R.sup.2a, R.sup.3, and R.sup.3a are as described herein.

##STR00001##

Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating diseases or disorders in a subject where the subject is in need of an inhibitor of MEK where the compound is according to formula (I): where R.sup.1, R.sup.2, R.sup.2a, R.sup.3, and R.sup.3a are as described herein.

##STR00001##

The present invention relates to the discovery of small molecule compounds that act as GLP-1R agonists and/or as positive allosteric modulators (PAMs) of GLP-1R. Such compounds are useful to treat, ameliorate, and/or prevent insulin resistance and/or diabetes in a mammal.

The present invention relates to the discovery of small molecule compounds that act as GLP-1R agonists and/or as positive allosteric modulators (PAMs) of GLP-1R. Such compounds are useful to treat, ameliorate, and/or prevent insulin resistance and/or diabetes in a mammal.

Provided herein are inhibitors of transmembrane protein 16A (TMEM 16A), a Ca.sup.2+-activated CI″ channel expressed widely in mammalian epithelia, as well as in vascular smooth muscle and some tumors and electrically excitable cells. TMEM16A inhibitors have potential utility for treatment or management of disorders of epithelial fluid and mucus secretion, hypertension, some cancers, pain, and other diseases.

Provided herein are inhibitors of transmembrane protein 16A (TMEM 16A), a Ca.sup.2+-activated CI″ channel expressed widely in mammalian epithelia, as well as in vascular smooth muscle and some tumors and electrically excitable cells. TMEM16A inhibitors have potential utility for treatment or management of disorders of epithelial fluid and mucus secretion, hypertension, some cancers, pain, and other diseases.